12:00 AM
 | 
Jun 09, 2008
 |  BioCentury  |  Product Development

Erbitux in NSCLC

Erbitux in NSCLC

Results from the Phase III FLEX trial of Erbitux cetuximab for advanced non-small cell lung cancer, presented last week at the American Society of Clinical Oncology meeting, compared to...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >